Furthermore, progressive MS is more strongly associated with increased cerebrospinal fluid GFAP levels compared to relapsing-remitting MS, suggesting that GFAP could serve as a useful marker for disease progression [11]. This evidence concerns the gene GFAP and myeloid sarcoma.